Figure 3

B16F10/GPI-IL-21 vaccination of C57BL/6 mice in combination with either miR200c overexpression or ZEB1 knockdown against B16F10 melanoma. (A) Images of the B16F10/ GPI-IL-21 vaccine immunized mice at 40 days after the mice were challenged by the different B16F10 cells. (B-D) Tumor volumes, tumor free mice and melanoma bearing mouse survival. (E) Images of metastasis nodules in murine lung. (F) The statistical analysis of metastatic tumor nodules. (G) The pathological changes in murine lung from the immunized mice that were challenged by the different B16F10 cells. (H) The statistical analysis of relative lung metastatic rates.